Edginton A - Search Results

1

Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies.

Malik P, Edginton A. Malik P, et al. Among authors: edginton a. Expert Opin Drug Metab Toxicol. 2018 Jun;14(6):585-599. doi: 10.1080/17425255.2018.1482278. Epub 2018 Jun 4. Expert Opin Drug Metab Toxicol. 2018. PMID: 29806953 Review.

2

Whole body physiologically-based pharmacokinetic models: their use in clinical drug development.

Edginton AN, Theil FP, Schmitt W, Willmann S. Edginton AN, et al. Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1143-52. doi: 10.1517/17425255.4.9.1143. Expert Opin Drug Metab Toxicol. 2008. PMID: 18721109 Review.

3

A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam.

Maharaj AR, Barrett JS, Edginton AN. Maharaj AR, et al. Among authors: edginton an. AAPS J. 2013 Apr;15(2):455-64. doi: 10.1208/s12248-013-9451-0. Epub 2013 Jan 24. AAPS J. 2013. PMID: 23344790 Free PMC article.

4

Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling.

Wang J, Edginton AN, Avant D, Burckart GJ. Wang J, et al. J Clin Pharmacol. 2015 Oct;55(10):1175-83. doi: 10.1002/jcph.524. Epub 2015 Jun 9. J Clin Pharmacol. 2015. PMID: 25907280

5

Pharmacokinetic Time Course Scaling of a Subcutaneously Administered Pegylated Peptide Conjugate for a First-in-Human Investigation.

Offman E, Edginton AN. Offman E, et al. Eur J Drug Metab Pharmacokinet. 2017 Feb;42(1):69-78. doi: 10.1007/s13318-016-0322-9. Eur J Drug Metab Pharmacokinet. 2017. PMID: 26838162 Clinical Trial.

6

Examining Small Intestinal Transit Time as a Function of Age: Is There Evidence to Support Age-Dependent Differences among Children?

Maharaj AR, Edginton AN. Maharaj AR, et al. Drug Metab Dispos. 2016 Jul;44(7):1080-9. doi: 10.1124/dmd.115.068700. Epub 2016 Mar 14. Drug Metab Dispos. 2016. PMID: 26977099 Review.

7

The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A.

McEneny-King A, Iorio A, Foster G, Edginton AN. McEneny-King A, et al. Among authors: edginton an. Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1313-1321. doi: 10.1080/17425255.2016.1214711. Epub 2016 Aug 19. Expert Opin Drug Metab Toxicol. 2016. PMID: 27539370

8

Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability.

Malik PRV, Hamadeh A, Phipps C, Edginton AN. Malik PRV, et al. Among authors: edginton an. J Pharmacokinet Pharmacodyn. 2017 Jun;44(3):277-290. doi: 10.1007/s10928-017-9515-3. Epub 2017 Mar 4. J Pharmacokinet Pharmacodyn. 2017. PMID: 28260166

9

Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.

Hornik CP, Wu H, Edginton AN, Watt K, Cohen-Wolkowiez M, Gonzalez D. Hornik CP, et al. Clin Pharmacokinet. 2017 Nov;56(11):1343-1353. doi: 10.1007/s40262-017-0525-5. Clin Pharmacokinet. 2017. PMID: 28290120 Free PMC article.

10

Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

Malik P, Phipps C, Edginton A, Blay J. Malik P, et al. Among authors: edginton a. Pharm Res. 2017 Dec;34(12):2579-2595. doi: 10.1007/s11095-017-2259-3. Epub 2017 Sep 18. Pharm Res. 2017. PMID: 28924691 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

138 results

Search Page

Filters